Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ATZUMI safely and effectively. See full prescribing information for ATZUMI. ATZUMI™ (dihydroergotamine) nasal powder Initial U.S. Approval: 1946
Medication labelWhy this: Advisory · dailymed-prescription
ATZUMI is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine. ATZUMI is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.
- generic_name
- dihydroergotamine mesylate
- product_names
- DIHYDROERGOTAMINE MESYLATE
- ndc
- 76978-101, 76978-101-11, 76978-101-08
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en